- ThinkSono, a UK-German medtech company, raised £2.1 million in the latest funding round, totaling £5 million raised to date.
- It specializes in ultrasound guidance solutions, with the flagship product Sono Guidance leveraging AI and real-time imaging for precise ultrasound-guided procedures.
- ThinkSono Guidance software allows non-ultrasound-trained healthcare staff to scan for DVT, streamlining the diagnostic process and improving patient outcomes.
- Attains Class IIb CE mark for flagship product, targeting UK and EU markets; awaits US FDA clearance.
- Partnerships were formed with hospitals across Europe, and strategic collaborations were made with US institutions like NYU Langone Health and Temple Health.
- The funding round was led by id4 ventures, with participation from Brandenburg Kapital, Calm Storm Ventures, and other investors.
Main AI News:
ThinkSono, the pioneering medtech firm specializing in ultrasound guidance solutions, has announced a significant milestone with the successful closure of its latest funding round, securing £2.1 million. This achievement brings the company’s total funding to approximately £5 million, reinforcing its position as a frontrunner in medical imaging innovation.
At the forefront of ThinkSono’s offerings is its flagship product, Sono Guidance, which integrates advanced AI algorithms with real-time imaging technology. This powerful combination provides healthcare professionals with unparalleled accuracy and precision during ultrasound-guided procedures, revolutionizing diagnostic capabilities.
One of the key applications of ThinkSono’s technology lies in the detection of deep vein thrombosis (DVT), a critical condition contributing to preventable hospital deaths worldwide. By enabling non-ultrasound-trained staff to conduct scans and facilitating prompt data review by qualified clinicians, ThinkSono’s software streamlines the diagnostic process, leading to more efficient patient management and improved outcomes.
Having secured the Class IIb CE mark for its flagship product, ThinkSono has made significant strides in making its technology accessible throughout the UK and EU. While awaiting clearance from the US FDA, the company has forged strategic partnerships with leading healthcare institutions across Europe, including prestigious establishments in the UK, Germany, and Greece.
Commenting on the recent funding round, CEO and Founder of ThinkSono, Fouad Al Noor, expressed his enthusiasm, stating, “This investment milestone will further fuel our mission to redefine the landscape of medical imaging technology. Our collaborations with renowned healthcare providers underscore our commitment to delivering innovative solutions that drive positive change in patient care.”
The latest funding round was led by id4 ventures, with participation from esteemed investors such as Brandenburg Kapital, Calm Storm Ventures, Dubai Angel Investors, CrowdCube, Cur8 Capital, as well as numerous prominent angel investors and vascular surgery clinicians. Michael Blaivas, ThinkSono’s Chief Medical Officer and Professor of Emergency Medicine, emphasized the transformative potential of the company’s technology, stating, “For decades, healthcare providers have grappled with the challenge of timely DVT diagnosis. ThinkSono’s innovative approach directly addresses this issue, offering a promising pathway to elevate the standard of patient care on a global scale.”
Conclusion:
The significant funding secured by ThinkSono underscores growing confidence in the company’s innovative ultrasound technology for DVT diagnosis. With advancements like Sono Guidance, ThinkSono is poised to disrupt the medical imaging market, offering solutions that enhance diagnostic accuracy and ultimately improve patient care outcomes. Strategic partnerships with renowned institutions further solidify its position, indicating potential market expansion and heightened competitiveness in the healthcare sector.
